Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016 (2016), Article ID 1745108, 7 pages
http://dx.doi.org/10.1155/2016/1745108
Clinical Study

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer

1Department of Respirology, Kyoto Prefectural University of Medicine, Kyoto, Japan
2Sendai Kousei Hospital, Sendai, Japan
3Department of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
4Department of Respiratory Medicine, Miyagi Cancer Center, Miyagi, Japan
5Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
6Department of Surgery, Kurume University School of Medicine, Kurume, Japan
7Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
8Kanagawa Cancer Center Research Institute, Yokohama, Japan
9Biostatistics Center, School of Medicine, Kurume University, Kurume, Japan
10Center for Clinical and Translational Research, Kyushu University, Fukuoka, Japan
11Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
12Division of Clinical Research, Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan
13Cancer Vaccine Center, Kurume University School of Medicine, Kurume, Japan

Received 25 January 2016; Accepted 7 April 2016

Academic Editor: Senthamil Selvan

Copyright © 2016 Koichi Takayama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Koichi Takayama, Shunichi Sugawara, Yasuo Saijo, et al., “Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer,” Journal of Immunology Research, vol. 2016, Article ID 1745108, 7 pages, 2016. doi:10.1155/2016/1745108